New drug tested on 26 patients with stubborn cancers
NCT ID NCT06098651
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-stage study tested a new drug called DCR-STAT3 in 26 adults with solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study is now complete, and results will help decide if further testing is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Next Oncology
Dallas, Texas, 75039, United States
-
Next Oncology
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.